INT92470

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 2000
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 5.46
Pain Relevance 5.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (CCL5) aging (CCL5) extracellular region (CCL5)
cell-cell signaling (CCL5) cytoplasm (CCL5)
Anatomy Link Frequency
microglial cell 8
blood 3
CSF 2
pelvis 2
T cell 2
CCL5 (Homo sapiens)
Pain Link Frequency Relevance Heat
chemokine 295 100.00 Very High Very High Very High
Inflammation 210 100.00 Very High Very High Very High
cytokine 153 100.00 Very High Very High Very High
Morphine 32 99.98 Very High Very High Very High
narcan 6 99.84 Very High Very High Very High
pain pelvic 6 99.48 Very High Very High Very High
Inflammatory response 15 99.04 Very High Very High Very High
endometriosis 6 99.02 Very High Very High Very High
Arthritis 100 98.10 Very High Very High Very High
dexamethasone 2 98.04 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 245 100.00 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 33 99.56 Very High Very High Very High
Reprotox - General 3 6 99.48 Very High Very High Very High
Endometriosis 9 99.02 Very High Very High Very High
Juvenile Chronic Polyarthritis 80 98.10 Very High Very High Very High
Demyelinating Disease 45 97.40 Very High Very High Very High
Infection 139 95.80 Very High Very High Very High
Neurodegenerative Disease 23 92.24 High High
Adhesions 44 91.40 High High
Central Nervous System Disease 5 90.34 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Prolonged treatment (8 d) with MPA resulted in 36% and 50% decreases in luciferase activity and RANTES protein production, respectively, whereas shorter treatment (2 or 4 d) with MPA had no significant effect.
Negative_regulation (decreases) of Gene_expression (production) of RANTES
1) Confidence 0.50 Published 2002 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 12050207 Disease Relevance 0.37 Pain Relevance 0.14
The clinical effectiveness of chronic progestin treatment in endometriosis-associated pelvic pain may be attributed to its inhibition of RANTES production and its suppression of inflammatory responses in the pelvis.
Negative_regulation (inhibition) of Gene_expression (production) of RANTES in pelvis associated with endometriosis, inflammatory response and pain pelvic
2) Confidence 0.44 Published 2002 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 12050207 Disease Relevance 0.53 Pain Relevance 0.29
Monomeric and GAG-binding-deficient mutants of CC chemokines RANTES/CCL5, MIP-1?
Negative_regulation (deficient) of Gene_expression (mutants) of RANTES associated with chemokine
3) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2909905 Disease Relevance 0.17 Pain Relevance 0.34
In a set of 11 JIA patients tested (4 persistent oligoarticular, 4 extended oligoarticular and 3 polyarticular), CCL5 expression was measured within the CD8+CD28+ T cells in paired samples of blood and synovial fluid T cells.
Negative_regulation (measured) of Gene_expression (expression) of CCL5 in blood associated with arthritis
4) Confidence 0.41 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526593 Disease Relevance 0.22 Pain Relevance 0.11
Treatment of highly purified microglial cell cultures with morphine (10(-8)-10(-6) M) potently inhibited RANTES production by lipopolysaccharide- and interleukin-1beta-stimulated cells.
Negative_regulation (inhibited) of Gene_expression (production) of RANTES in microglial cell associated with morphine
5) Confidence 0.37 Published 2000 Journal J. Psychopharmacol. (Oxford) Section Abstract Doc Link 11106302 Disease Relevance 0.08 Pain Relevance 0.81
The inhibitory effects of morphine on RANTES production and on chemotaxis were blocked by naloxone and beta-funaltrexamine, indicating that morphine mediated its suppressive effects via activation of microglial p-opioid receptors.
Negative_regulation (blocked) of Gene_expression (production) of RANTES associated with narcan, opioid receptor and morphine
6) Confidence 0.37 Published 2000 Journal J. Psychopharmacol. (Oxford) Section Abstract Doc Link 11106302 Disease Relevance 0.07 Pain Relevance 0.97
Morphine inhibits human microglial cell production of, and migration towards, RANTES.
Negative_regulation (inhibits) of Gene_expression (production) of RANTES in microglial cell associated with morphine
7) Confidence 0.37 Published 2000 Journal J. Psychopharmacol. (Oxford) Section Title Doc Link 11106302 Disease Relevance 0.10 Pain Relevance 0.89
In addition, its action via progesterone response element cis-elements, PR appeared to inhibit trans-activation of a nuclear factor-kappaB-responsive element, further suppressing RANTES expression.
Negative_regulation (suppressing) of Gene_expression (expression) of RANTES
8) Confidence 0.37 Published 2002 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 12050207 Disease Relevance 0.29 Pain Relevance 0.26
As observed above, ICAM-1, IL-6, IL-8, GM-CSF, RANTES, MCP-1, GROalpha, NAP-2, and ENA-78 expression was reduced by the IKK inhibitors.
Negative_regulation (reduced) of Gene_expression (expression) of RANTES
9) Confidence 0.19 Published 2006 Journal Mol. Pharmacol. Section Abstract Doc Link 16687566 Disease Relevance 0.42 Pain Relevance 0.41
In a set of 11 JIA patients tested (4 persistent oligoarticular, 4 extended oligoarticular and 3 polyarticular), CCL5 expression was measured within the CD8+CD28+ T cells in paired samples of blood and synovial fluid T cells.
Negative_regulation (measured) of in synovial fluid Gene_expression (expression) of CCL5 in blood associated with arthritis
10) Confidence 0.14 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526593 Disease Relevance 0.22 Pain Relevance 0.11
Three specific chemokines—RANTES, MIP1?
Negative_regulation (Three) of Gene_expression (chemokines) of RANTES associated with chemokine
11) Confidence 0.12 Published 2003 Journal Biol Proced Online Section Body Doc Link PMC153847 Disease Relevance 0.90 Pain Relevance 0.44
Potent and sustained expression of the chemokines CCL2, CCL3, CCL4 and CCL5, in addition to that of IL-6 and IL-8, contributes to maintaining the inflammatory environment created by microglia in response to B. burgdorferi
Negative_regulation (sustained) of Gene_expression (expression) of CCL5 in microglia associated with chemokine and inflammation
12) Confidence 0.07 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2771360 Disease Relevance 0.48 Pain Relevance 0.21
Potent and sustained expression of the chemokines CCL2, CCL3, CCL4 and CCL5, in addition to that of IL-6 and IL-8, contributes to maintaining the inflammatory environment created by microglia in response to B. burgdorferi
Negative_regulation (Potent) of Gene_expression (expression) of CCL5 in microglia associated with chemokine and inflammation
13) Confidence 0.07 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2771360 Disease Relevance 0.48 Pain Relevance 0.21
Both methods inhibited gene expression of VEGF-A, VEGF-C (angiogenic molecules), GRO (cytokine with inflammatory and growth-regulatory properties), RANTES (cytokine regulating T cell response) and SDF-1(a ligand for the chemokine receptor CXCR4) even at 24 h PI.
Negative_regulation (inhibited) of Gene_expression (expression) of RANTES in T cell associated with chemokine, inflammation and cytokine
14) Confidence 0.06 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2820536 Disease Relevance 0.64 Pain Relevance 0.44
Although CD19+ B-cell reduction occurs rapidly, recovery from the nadir is seen earlier and more pronounced compared with T cells.56–60 Recent evidence indicates that cladribine may also impede the influx of T cells into the CNS, and might also influence levels of soluble adhesion molecular levels such as sICAM or sE-Selectin.61,62 In addition, cladribine may exert immunomodulatory effects on proinflammatory cytokine profiles: Mean values of Interleukin-2 (IL-2) and soluble interleukin-2 receptor levels measured 12 months after cladribine treatment for chronic progressive MS were found to be lowered.63 IL-8-levels were decreased in cerebrospinal fluid (CSF) of cladribine-treated RRMS patients, whereas CCL-5 levels were decreased both in CSF and serum.64 These and other data suggests that cladribine not only has an leukocyte depleting effect, but also may exert a direct effect on effectors T-cell function.59,65

Pharmacokinetics of cladribine

Negative_regulation (decreased) of Gene_expression (levels) of CCL-5 in CSF associated with multiple sclerosis, central nervous system, adhesions and cytokine
15) Confidence 0.03 Published 2010 Journal Drug Des Devel Ther Section Body Doc Link PMC2915536 Disease Relevance 0.46 Pain Relevance 0.24

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox